These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 37227492)

  • 21. Characteristics and therapeutic approaches for patients diagnosed with T-ALL/LBL exhibiting t(8;14)(q24;q11)/TCRA/D:MYC translocation.
    Zhang X; Wang T; Zhang Y; Wang F; Chen J; Ni J; Sun R; Wei Z; Zhang G; Li W; Li J; Lu P
    Leuk Lymphoma; 2023 Dec; 64(13):2133-2139. PubMed ID: 37674391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma.
    Summers RJ; Teachey DT
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):718-725. PubMed ID: 35941070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphoblastic Lymphoma: a Concise Review.
    Intermesoli T; Weber A; Leoncin M; Frison L; Skert C; Bassan R
    Curr Oncol Rep; 2022 Jan; 24(1):1-12. PubMed ID: 35059993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study.
    Yasuda S; Najima Y; Konishi T; Yamada Y; Nagata A; Takezaki T; Kaito S; Kurosawa S; Sakaguchi M; Harada K; Shingai N; Yoshioka K; Inamoto K; Mukae J; Toya T; Igarashi A; Shimizu H; Kobayashi T; Kakihana K; Sakamaki H; Kawamata N; Ohashi K; Doki N
    Leuk Res; 2021 Sep; 108():106627. PubMed ID: 34062327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Precursor B- or T-lymphoblastic lymphoma presenting with cutaneous involvement: a series of 13 cases including 7 cases of cutaneous T-lymphoblastic lymphoma.
    Lee WJ; Moon HR; Won CH; Chang SE; Choi JH; Moon KC; Lee MW
    J Am Acad Dermatol; 2014 Feb; 70(2):318-25. PubMed ID: 24314877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isatuximab monotherapy in patients with refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma: Phase 2 study.
    Boissel N; Chevallier P; Doronin V; Griskevicius L; Maschan A; McCloskey J; Rambaldi A; Rossi G; Sokolov A; Wartiovaara-Kautto U; Oprea C; Abbadessa G; Gosselin A; Macé S; Thomas X
    Cancer Med; 2022 Mar; 11(5):1292-1298. PubMed ID: 35106962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diverse mutations and structural variations contribute to Notch signaling deregulation in paediatric T-cell lymphoblastic lymphoma.
    Salmerón-Villalobos J; Ramis-Zaldivar JE; Balagué O; Verdú-Amorós J; Celis V; Sábado C; Garrido M; Mato S; Uriz J; Ortega MJ; Gutierrez-Camino A; Sinnett D; Illarregi U; Carron M; Regueiro A; Galera A; Gonzalez-Farré B; Campo E; Garcia N; Colomer D; Astigarraga I; Andrés M; Llavador M; Martin-Guerrero I; Salaverria I
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29926. PubMed ID: 36000950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design of a targeted next-generation DNA sequencing panel for pediatric T-cell lymphoblastic lymphoma to unravel biology and optimize treatment.
    Ruether C; Wuensch C; Randau G; Michgehl U; Trautmann M; Hartmann W; Sandmann S; Dugas M; Khanam T; Burkhardt B
    Genes Chromosomes Cancer; 2022 Aug; 61(8):459-470. PubMed ID: 35278000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.
    Paolino J; Dimitrov B; Apsel Winger B; Sandoval-Perez A; Rangarajan AV; Ocasio-Martinez N; Tsai HK; Li Y; Robichaud AL; Khalid D; Hatton C; Gillani R; Polonen P; Dilig A; Gotti G; Kavanagh J; Adhav AA; Gow S; Tsai J; Li Y; Ebert BL; Van Allen EM; Bledsoe J; Kim AS; Tasian SK; Cooper SL; Cooper TM; Hijiya N; Sulis ML; Shukla NN; Magee JA; Mullighan CG; Burke MJ; Luskin MR; Mar BG; Jacobson MP; Harris MH; Stegmaier K; Place AE; Pikman Y
    Clin Cancer Res; 2023 Nov; 29(22):4613-4626. PubMed ID: 37725576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells.
    Feng J; Xu H; Cinquina A; Wu Z; Chen Q; Zhang P; Wang X; Shan H; Xu L; Zhang Q; Sun L; Zhang W; Pinz KG; Wada M; Jiang X; Hanes WM; Ma Y; Zhang H
    Stem Cell Rev Rep; 2021 Apr; 17(2):652-661. PubMed ID: 33410096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances.
    Liu J; Zhang Y; Guo R; Zhao Y; Sun R; Guo S; Lu W; Zhao M
    Front Immunol; 2023; 14():1170968. PubMed ID: 37215124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for T lymphoblastic leukemia/lymphoma].
    Luo L; Jiao Y; Yang P; Li Y; Huang WY; Ke XY; Zou DH; Jing HM
    Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):388-394. PubMed ID: 37550188
    [No Abstract]   [Full Text] [Related]  

  • 33. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
    Pan J; Tan Y; Wang G; Deng B; Ling Z; Song W; Seery S; Zhang Y; Peng S; Xu J; Duan J; Wang Z; Yu X; Zheng Q; Xu X; Yuan Y; Yan F; Tian Z; Tang K; Zhang J; Chang AH; Feng X
    J Clin Oncol; 2021 Oct; 39(30):3340-3351. PubMed ID: 34324392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent developments in the management of T-cell precursor acute lymphoblastic leukemia/lymphoma.
    Fielding AK; Banerjee L; Marks DI
    Curr Hematol Malig Rep; 2012 Jun; 7(2):160-9. PubMed ID: 22476945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study.
    Candoni A; Lazzarotto D; Ferrara F; Curti A; Lussana F; Papayannidis C; Del Principe MI; Bonifacio M; Mosna F; Delia M; Minetto P; Gottardi M; Fracchiolla N; Mancini V; Forghieri F; Zappasodi P; Cerrano M; Vitale A; Audisio E; Trappolini S; Romani C; Defina M; Imbergamo S; Ciccone N; Santoro L; Cambò B; Iaccarino S; Dargenio M; Aprile L; Chiaretti S; Fanin R; Pizzolo G; Foà R
    Am J Hematol; 2020 Dec; 95(12):1466-1472. PubMed ID: 32777149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymphoblastic lymphoma in childhood and adolescence.
    Schmidt E; Burkhardt B
    Pediatr Hematol Oncol; 2013 Sep; 30(6):484-508. PubMed ID: 23621872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
    DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia.
    Patel J; Gao X; Wang H
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
    Candoni A; Lazzarotto D; Petruzzellis G
    Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia.
    Tan Y; Shan L; Zhao L; Deng B; Ling Z; Zhang Y; Peng S; Xu J; Duan J; Wang Z; Yu X; Zheng Q; Xu X; Tian Z; Zhang Y; Zhang J; Chang AH; Feng X; Pan J
    J Hematol Oncol; 2023 Apr; 16(1):34. PubMed ID: 37020231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.